Clinical Trial Update: A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating SHR-A2102 in combination with Adebrelimab for locally advanced or metastatic urothelial carcinoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Adebrelimab (adebrelimab)
• SHR-A2102

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Locally Advanced or Metastatic Urothelial Carcinoma | Phase 3 | Status: RECRUITING